|
CYP2B6 polymorphism
|
|
0.030 |
GeneticVariation
|
BEFREE |
The post-menopausal status was related to high levels of asthenia in docetaxel protocol whereas CYP2B6 polymorphism (rs3745274) was related to high levels in FAC protocol.
|
31056713 |
2020 |
|
Tuberculosis
|
|
0.030 |
GeneticVariation
|
BEFREE |
A total of 418 patients with HIV-1 mono-infection, HIV-1 and Tuberculosis coinfection and symptomatic P. falciparum malaria were genotyped for the CYP2B6 c.516G>T SNP using Restriction Fragment Length Polymorphism (RFLP).
|
30818046 |
2019 |
|
Tuberculosis
|
|
0.030 |
GeneticVariation
|
BEFREE |
The G516T polymorphism in the CYP2B6 gene is a key predictor of the therapeutic response to treatment in TB patients.
|
25271170 |
2015 |
|
Tuberculosis
|
|
0.030 |
GeneticVariation
|
BEFREE |
HIV-infected patients with or without TB who had received combination antiretroviral therapy containing efavirenz (600 mg daily) for two weeks or greater were enrolled for determinations of CYP2B6 G516T polymorphism and plasma efavirenz concentrations with the use of polymerase-chain-reaction restriction fragment-length polymorphism and high-performance liquid chromatography, respectively.
|
24551111 |
2014 |
|
CYP2B6 polymorphism
|
|
0.030 |
GeneticVariation
|
BEFREE |
The aim of this study was to evaluate the clinical and economic impact of efavirenz (EFV) dose adjustment by monitoring plasma concentrations and pharmacogenetic analysis of the 516G>T CYP2B6 polymorphism.
|
24956253 |
2014 |
|
CYP2B6 polymorphism
|
|
0.030 |
GeneticVariation
|
BEFREE |
Previous studies outside of the United Kingdom have shown associations between the CYP2B6 polymorphism G516T and increased toxicity.
|
19486190 |
2009 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
The purpose of this study was to measure the frequency of three CYP2B6 [CYP2B6*4 (rs2279343), CYP2B6*5 (rs3211371) and CYP2B6*9 (rs3745274)] alleles in patients with breast cancer receiving cyclophosphamide (CP) therapy and test whether these variants are predictors of CP-associated toxicity and efficacy.
|
25428516 |
2015 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The purpose of this study was to measure the frequency of three CYP2B6 [CYP2B6*4 (rs2279343), CYP2B6*5 (rs3211371) and CYP2B6*9 (rs3745274)] alleles in patients with breast cancer receiving cyclophosphamide (CP) therapy and test whether these variants are predictors of CP-associated toxicity and efficacy.
|
25428516 |
2015 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
To assess potential associations between two functional polymorphisms CYP2B6_516_G>T (rs3745274) and CYP2B6_785_A>G (rs2279343) and breast cancer risk, we established a specific matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay.
|
23824676 |
2014 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
To assess potential associations between two functional polymorphisms CYP2B6_516_G>T (rs3745274) and CYP2B6_785_A>G (rs2279343) and breast cancer risk, we established a specific matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay.
|
23824676 |
2014 |
|
Asthenia
|
|
0.010 |
GeneticVariation
|
BEFREE |
The post-menopausal status was related to high levels of asthenia in docetaxel protocol whereas CYP2B6 polymorphism (rs3745274) was related to high levels in FAC protocol.
|
31056713 |
2020 |
|
Coinfection
|
|
0.010 |
GeneticVariation
|
BEFREE |
A total of 418 patients with HIV-1 mono-infection, HIV-1 and Tuberculosis coinfection and symptomatic P. falciparum malaria were genotyped for the CYP2B6 c.516G>T SNP using Restriction Fragment Length Polymorphism (RFLP).
|
30818046 |
2019 |
|
Malaria, Falciparum
|
|
0.010 |
GeneticVariation
|
BEFREE |
A total of 418 patients with HIV-1 mono-infection, HIV-1 and Tuberculosis coinfection and symptomatic P. falciparum malaria were genotyped for the CYP2B6 c.516G>T SNP using Restriction Fragment Length Polymorphism (RFLP).
|
30818046 |
2019 |
|
Systemic Scleroderma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Patients with systemic sclerosis (n = 10) or multiple sclerosis (n = 10), genotyped for the allelic variants of CYP2C9*2 and CYP2C9*3 and of the CYP2B6 G516T polymorphism, were treated with 50 mg cyclophosphamide/kg daily for 4 days.
|
28083951 |
2017 |
|
Absence of sensation
|
|
0.010 |
GeneticVariation
|
BEFREE |
From all the analysed changes, only polymorphism c.516G>T in the CYP2B6 gene and BMI affect the metabolism rate of propofol and may play an important role in the optimisation of propofol anaesthesia.
|
27826892 |
2017 |
|
Immunologic Deficiency Syndromes
|
|
0.010 |
GeneticVariation
|
BEFREE |
We characterized the HIV-1-infected children (n = 60) for the CYP2B6 c.516G>T, c.785A>G, c.983T>C, and c.1459C>T single nucleotide polymorphisms (SNPs).
|
28816644 |
2017 |
|
Multiple Sclerosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Patients with systemic sclerosis (n = 10) or multiple sclerosis (n = 10), genotyped for the allelic variants of CYP2C9*2 and CYP2C9*3 and of the CYP2B6 G516T polymorphism, were treated with 50 mg cyclophosphamide/kg daily for 4 days.
|
28083951 |
2017 |
|
HIV disease progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
We conclude that CYP2B6 c.516G>T and CYP2B6 c.983T>C could be important sources of nevirapine pharmacokinetic variability that could be considered for dosage optimization, while CYP1A2 g.-163C>A seems to be associated with HIV disease progression.
|
26348712 |
2015 |
|
Toxic Epidermal Necrolysis
|
|
0.010 |
GeneticVariation
|
BEFREE |
CYP2B6 G516T and T983C single nucleotide polymorphisms (SNPs) were found to be associated with SJS/TEN susceptibility.
|
23774940 |
2013 |
|
Schwartz-Jampel Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
CYP2B6 G516T and T983C single nucleotide polymorphisms (SNPs) were found to be associated with SJS/TEN susceptibility.
|
23774940 |
2013 |
|
MYELODYSPLASTIC SYNDROME
|
|
0.010 |
GeneticVariation
|
BEFREE |
MDS was unrelated to the genotype and allele frequencies of c.516G>T SNP in CYP2B6.
|
20878158 |
2011 |
|
leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
T allele of CYP2B6 516G>T SNP may be one of the risk factors predisposing to the pathogenesis of a majority of ALL and AML, but has no relationship with B-ALL and leukemia with or without chromosome abnormalities.
|
20878158 |
2011 |
|
Congenital chromosomal disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
T allele of CYP2B6 516G>T SNP may be one of the risk factors predisposing to the pathogenesis of a majority of ALL and AML, but has no relationship with B-ALL and leukemia with or without chromosome abnormalities.
|
20878158 |
2011 |
|
Childhood Acute Lymphoblastic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
T allele of CYP2B6 516G>T SNP may be one of the risk factors predisposing to the pathogenesis of a majority of ALL and AML, but has no relationship with B-ALL and leukemia with or without chromosome abnormalities.
|
20878158 |
2011 |
|
Acute lymphocytic leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
T allele of CYP2B6 516G>T SNP may be one of the risk factors predisposing to the pathogenesis of a majority of ALL and AML, but has no relationship with B-ALL and leukemia with or without chromosome abnormalities.
|
20878158 |
2011 |